EGFR and lung adenocarcinoma: EGFR-driven lung adenocarcinomas have a low tumor mutational burden (TMB)52 (Fig. 6A), and our mouse data suggest that inactivation of several putative tumor suppressor genes are deleterious and thus unlikely to be observed in the human data, even as passengers.